Multiple inflammatory diseases are characterized by dysregulation of tumor necrosis factor alpha (TNFα), and the development of anti-TNFα inhibitors has been a milestone in the treatment of rheumatoid arthritis (RA), inflammatory bowel disease, ankylosing spondylitis, and psoriatic arthritis. The gene discussed is TNF; the disease is ankylosing spondylitis.